Cargando…
Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)
BACKGROUND: The primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD) is reducing low-density lipoprotein cholesterol (LDL-C). This was a multicenter, randomized, double-blind, double-dummy study in patients with type 2 diabetes mellitus (T2DM). METHODS: Adul...
Autores principales: | Bardini, Gianluca, Giorda, Carlo B, Pontiroli, Antonio E, Le Grazie, Cristina, Rotella, Carlo M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887787/ https://www.ncbi.nlm.nih.gov/pubmed/20492655 http://dx.doi.org/10.1186/1475-2840-9-20 |
Ejemplares similares
-
Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
por: Rotella, Carlo M, et al.
Publicado: (2010) -
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)
por: Mihaylova, Borislava, et al.
Publicado: (2016) -
Preformulation Studies of Ezetimibe-Simvastatin Solid Dispersions in the Development of Fixed-Dose Combinations
por: Górniak, Agata, et al.
Publicado: (2022) -
Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review
por: Chauhan, Dhruva, et al.
Publicado: (2022) -
Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia
por: Visseren, F. L. J.
Publicado: (2011)